Novavax (NVAX)
Novavax Enterprise Value: 142.14M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NVAX Enterprise Value Rankings
| Overall | 24th percentile | 3240 of 4271 |
| Sector | 37th percentile | 307 of 493 in Healthcare |
| Industry | 45th percentile | 84 of 154 in Biotechnology |
NVAX Enterprise Value Range, Past 5 Years
| Minimum | 73.31M | Mar 2009 |
| Maximum | 340.36M | Sep 2009 |
| Average | 199.58M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
You may also be interested in these NVAX related companies
NVAX News
NOVAVAX Launches Additional Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate
May 09, 8:04AM Benzinga
May 09, 8:04AM Benzinga
$ZGNX and $GERN becoming even more interesting now $NVAX not so bad today
about 22 days ago by micheleciani
about 22 days ago by micheleciani
Market Wrap Video + Additions to Watch List http://stks.co/3iY4 including: $CAR $CPTS $GWR $NVAX $PBY $PPR
about 23 days ago by StockTiger
about 23 days ago by StockTiger
$NVAX http://stks.co/3iCA for a move to 200-day ok % gain if so -n Over $1.44 to 200-day
about 23 days ago by StockTiger
about 23 days ago by StockTiger
@Bleedblue i own both lol and $GALE is making me sad but $NVAX is making me happy
about 23 days ago by MisterDevin
about 23 days ago by MisterDevin
Listen to $NVAX Q1 2012 earnings call - live at 10:00 AM, ondemand after - http://stks.co/3flk
about 27 days ago by earningscast
about 27 days ago by earningscast
$NVAX Reports First Quarter 2012 Financial Results http://stks.co/3fh4 Good
about 27 days ago by micheleciani
about 27 days ago by micheleciani
Stock on our radar $ZGNX and $NVAX both more than +10% in the last few days
about 28 days ago by micheleciani
about 28 days ago by micheleciani
NOVAVAX Launches Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate
May 02, 8:08AM Benzinga
May 02, 8:08AM Benzinga
Novavax (NVAX) Commences Enrollment in A/H5N1 Vaccine Candidate Phase I
May 02, 8:03AM Street Insider
May 02, 8:03AM Street Insider
@JVerns Yea. $NVAX not bad, a lot of volume, been holding that for a while. $GALE has huge upside, long wait though, I'll just cont. to add
about 30 days ago by MisterDevin
about 30 days ago by MisterDevin
@MisterDevin In the same boat. $NVAX could get even more interesting tomorrow
about 30 days ago by JVerns
about 30 days ago by JVerns
NOVAVAX to Present Results From Phase I RSV Study at XIV International Symposium on Respiratory Viral Infections
Mar 22, 9:52AM GlobeNewswire
Mar 22, 9:52AM GlobeNewswire
NOVAVAX Appoints John A. Herrmann III, Vice President and General Counsel
Mar 08, 9:00AM GlobeNewswire
Mar 08, 9:00AM GlobeNewswire
Novavax (NVAX) Commences Enrollment in Quadrivalent Seasonal VLP Phase II
Mar 01, 4:34PM Street Insider
Mar 01, 4:34PM Street Insider
NOVAVAX to Report 2011 Fourth-Quarter and Year-End Financial Results on March 9, 2012
Feb 24, 8:00AM GlobeNewswire
Feb 24, 8:00AM GlobeNewswire
Novavax (NVAX) India JV Makes Significant Vaccine-Development Program Progress
Jan 03, 8:17AM Street Insider
Jan 03, 8:17AM Street Insider
NOVAVAX Reports Progress Under Joint Venture in India With Cadila Pharmaceuticals
Jan 03, 8:06AM Benzinga
Jan 03, 8:06AM Benzinga
NOVAVAX to Present at 23rd Annual Piper Jaffray Health Care Conference
Nov 28, 12:17PM GlobeNewswire
Nov 28, 12:17PM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NVAX | 1.235 | -0.04 | -3.52% | 155.61M |
| NPK | 66.07 | -0.36 | -0.54% | 457.04M |
| NPF | 15.05 | -0.01 | -0.07% | |
| NPD | 2.62 | -0.17 | -6.09% | 287.73M |
| NPBC | 8.80 | -0.14 | -1.57% | 1.361B |
| NHC | 43.24 | -0.25 | -0.57% | 602.77M |
| NGZ | 12.75 | +0.09 | +0.71% | |
| NGX | 15.31 | -0.03 | -0.20% | |
| NGT | 21.35 | -0.15 | -0.70% | 125.96M |
| NGSX | 0.35 | -0.02 | -5.41% | 11.07M |
